4506 — Sumitomo Pharma Co Income Statement
0.000.00%
Last trade - 00:00
- ¥164bn
- ¥533bn
- ¥556bn
- 15
- 53
- 30
- 18
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 459,267 | 482,732 | 515,952 | 560,035 | 555,544 |
Cost of Revenue | |||||
Gross Profit | 345,714 | 353,687 | 378,307 | 402,919 | 377,050 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 401,383 | 399,493 | 444,728 | 499,801 | 632,523 |
Operating Profit | 57,884 | 83,239 | 71,224 | 60,234 | -76,979 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 65,046 | 83,947 | 77,851 | 82,961 | -47,920 |
Provision for Income Taxes | |||||
Net Income After Taxes | 48,627 | 35,918 | 36,829 | 40,600 | -96,714 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 48,627 | 40,753 | 56,219 | 56,413 | -74,512 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 48,627 | 40,753 | 56,219 | 56,413 | -74,512 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 135 | 140 | 164 | 142 | -150 |
Dividends per Share |